Half-Life Visualizer

Published encyclopedia entries with chartable half-life data: 68.

Interactive plasma half-life decay charts and pharmacokinetic references for research compounds with chartable data. For each compound, the visualizer shows a plasma-concentration decay curve alongside plasma half-life, duration of active effect, bioavailability by administration route, steady-state timing, and washout period.

What is plasma half-life and why does it matter?

Plasma half-life (t½) is the time required for compound concentration in blood plasma to fall by 50%. Published study parameters use this measure to describe concentration profiles and study duration; findings vary by compound and research method.

Compounds covered

The visualizer includes pharmacokinetic data for the following compound categories and specific peptides:

  • Regenerative & Repair: BPC-157, TB-500 (Thymosin Beta-4), GHK-Cu, BPC-157 & TB-500 blend
  • GLP-1, GIP & Metabolic Peptides: Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Dulaglutide, Oxytocin
  • Growth Hormone Axis: Ipamorelin, CJC-1295, CJC-1295 DAC, GHRP-2, GHRP-6, Hexarelin, Tesamorelin, Sermorelin, MK-677 (Ibutamoren)
  • Nootropic & Cognitive: Selank, Semax, Dihexa, Epithalon, P21
  • Melanocortin & Sexual Function: PT-141 (Bremelanotide), Melanotan II
  • Immune Modulating: Thymosin Alpha-1 (Tα1), LL-37
  • Longevity & Mitochondrial: SS-31 (Elamipretide), MOTS-c, Humanin, NAD+
  • Amino Acids & Antioxidants: Glutathione, L-Glutamine, Taurine, L-Carnitine, NAC
  • Hormonal & Reproductive: HCG, Kisspeptin-10
  • Khavinson Bioregulators: Epithalon, Pinealon, Vilon, Thymalin, Cortexin, Vesugen, Testagen, Chonluten, Sigumir, Bonomarlot, Ventfort, Crystagen, Libidon, Endoluten, Cartalax, Gotratix
  • Small Molecules & Metabolic: AOD-9604, 5-Amino-1MQ, Methylene Blue
  • Anti-Cancer Research: IGF-1 LR3
  • Cosmetic & Skin: SNAP-8, Leuphasyl

How to use the Half-Life Visualizer

Search or browse the compound list on the left to select any peptide. The visualizer renders its plasma decay curve with reference lines marking the half-life point (50% remaining, amber) and the approximate washout point (~97% cleared, red). Below the chart, stat cards show duration of active effect, bioavailability by administration route, steady-state timing, and washout period. Use Compare Mode to plot two compounds on the same time axis side by side.

Understanding the pharmacokinetic stats

Duration of Active Effect
The window during which the compound is expected to exert a meaningful biological effect, distinct from plasma half-life when downstream effects outlast plasma clearance, as with Khavinson bioregulators.
Bioavailability by Route
How much of the compound reaches systemic circulation through a route of administration: subcutaneous (SC), intramuscular (IM), intravenous (IV), intranasal, or oral. Most peptides are poorly bioavailable orally due to GI degradation.
Steady-State Timing
The time for plasma levels to reach a steady state across repeated study intervals. The timing depends on the compound and reported research method.
Washout Period
The time required for the compound to clear sufficiently from the system, approximately 5 half-lives for most compounds. At that point, less than 3% remains in plasma.

Khavinson bioregulator note

Khavinson bioregulators (Epithalon, Pinealon, Vilon, Thymalin, and related short peptides) have plasma half-lives measured in minutes but trigger gene-expression changes that persist for weeks to months. The decay chart shows plasma clearance only. The biologically relevant duration is the gene-expression effect window shown in the stat cards.